First-in-human phase I clinical trial of NY-ESO-1 protein cancer vaccine with a novel adjuvant MIS416, NOD2 and TLR9 stimulant, for patients with NY-ESO-1 expressing solid tumors

Authors :: Katsunori Uchida
Takeshi Sasaki
Naoyuki Katayama
Yasutaka Tono
Hiroaki Ikeda
Yoshihiro Miyahara
Eiichi Sato
Norihito Soga
Shinichi Kageyama
Taizo Shiraishi
Yoshiki Sugimura
Gill A Webster
Toshiro Mizuno
Naozumi Harada
Hiroshi Shiku
Mikiya Ishihara
Yasuhide Hori
Hideki Kanda
Source :: Journal of Clinical Oncology. 36:e15176-e15176
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: e15176Background: Complexes of Cholesteryl pullulan and NY-ESO-1 antigen (CHP-NY-ESO-1) present multiple epitope peptides to both the MHC class I and class II pathways. MIS416 is a non-toxic microp...

Full Text Access

Tools